John Henegan, MD
Hematology & Oncology · Jackson, MSNPI 1114188471
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (38.5%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. 60 manufacturers reported payments, led by Pfizer at 26.3% of the total. Reporting peaked in 2022 at $10,608 and has fallen 61.2% since, to $4,117 in 2025. Among hematology & oncology clinicians in MS with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 726 payments — averaging $48.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$9K
- Sanofi$8K
- Exelixis Inc.$5K
- AVEO Pharmaceuticals, Inc.$2K
- Johnson & Johnson$878
- Incyte Corporation$866
- plus $9K from 54 others
Across 50 payments — averaging $22,567 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$761K
- Merck$207K
- Astrazeneca UK Limited$80K
- Pfizer$23K
- Seagen Inc.$22K
- Pharmacyclics LLC, An Abbvie Company$19K
- plus $18K from 2 others
What the payments were for
- Consulting fees$13,47038%
- Speaking & faculty fees$3,95011%
- Travel & lodging$3,60610%
- Food & beverage$13,42038%
- Education$5762%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$35,022 in reported general payments places this provider in the 90th percentile of 57 hematology & oncology providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 84 | $888,754 |
| Abiraterone Acetate | 391 | $593,387 |
| FotivdaTivozanib Hcl | 18 | $534,886 |
| CabometyxCabozantinib S-Malate | 20 | $430,801 |
| InlytaAxitinib | 25 | $334,678 |
| ErleadaApalutamide | 25 | $278,590 |
| WeliregBelzutifan | 24 | $169,773 |
| EliquisApixaban | 37 | $29,019 |
| Fentanyl | 30 | $5,275 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 177 | $3,149 |
| Tamsulosin Hcl | 120 | $1,897 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 98 | $1,814 |
| Ondansetron Hcl | 72 | $1,546 |
| Prednisone | 343 | $1,376 |
| Morphine Sulfate ErMorphine Sulfate | 40 | $1,366 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi | $528 | $888,75484 claims |
| Exelixis Inc.Cabometyx | $4,669 | $430,80120 claims |
| PfizerInlyta, Eliquis | $9,210 | $363,69762 claims |
| Johnson & JohnsonErleada | $878 | $278,59025 claims |
| MerckWelireg | $572 | $169,77324 claims |
| Lilly USA, LLCOlanzapine | $45 | $53925 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 57 hematology & oncology providers in Mississippi.
Other hematology & oncology in Jackson
- Carter MilnerJackson$248K
- Guangzhi QuJackson$59K
- Barbara CraftJackson$11K
- Grace ShumakerJackson$7K
- Justin BakerJackson$3K
- Katherine ThielJackson$2K
- Bobby WilkersonJackson$2K
- Solly ChedidPascagoula$1.7M
- Jennifer EubanksMeridian$44K
- Daniel PattersonPascagoula$36K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.